TrademarkDir
OCTAVE
LIVE

Serial Number

87784843

Owner

Ulthera, Inc.

Attorney

Terry K. Tullis

First Use Date

Dec 29, 2020

Filing Date

Feb 5, 2018

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

OCTAVE Trademark

Serial Number: 87784843 • Registration: 6667008

OCTAVE is a trademark filed by Ulthera, Inc. on February 5, 2018. The trademark is classified under Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Ulthera, Inc. (50 trademarks)

6501 Six Forks Road
Raleigh, NC 27615

Entity Type: 03

MERZ PHARMA GMBH & CO. KGAA (186 trademarks)

FRANKFURT 60318 , DE

Entity Type: 13

Trademark Details

Filing Date

February 5, 2018

Registration Date

March 8, 2022

First Use Anywhere

December 29, 2020

First Use in Commerce

December 29, 2020

Published for Opposition

May 1, 2018

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 20, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 20, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 20, 2023 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 20, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 20, 2023 COAR
REGISTERED-PRINCIPAL REGISTER
Mar 8, 2022 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Feb 3, 2022 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Feb 2, 2022 CNPR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 13, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 13, 2022 CRFA
ASSIGNED TO LIE
Jan 12, 2022 ALIE
NOTICE OF REVIVAL - E-MAILED
Jan 11, 2022 NREV
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 10, 2022 TROA
PETITION TO REVIVE-GRANTED
Jan 10, 2022 PETG
TEAS PETITION TO REVIVE RECEIVED
Jan 10, 2022 PROA
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jan 7, 2022 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jan 7, 2022 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 26, 2021 GNRN
NON-FINAL ACTION E-MAILED
Jun 26, 2021 GNRT
SU - NON-FINAL ACTION - WRITTEN
Jun 26, 2021 CNRT
STATEMENT OF USE PROCESSING COMPLETE
Jun 25, 2021 SUPC
USE AMENDMENT FILED
Jun 21, 2021 IUAF
TEAS STATEMENT OF USE RECEIVED
Jun 21, 2021 EISU
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 17, 2021 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jun 17, 2021 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 17, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 17, 2021 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 5, 2021 EXRA
SOU EXTENSION 5 GRANTED
Jan 4, 2021 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 4, 2021 AITU
SOU EXTENSION 5 FILED
Dec 14, 2020 EXT5
SOU TEAS EXTENSION RECEIVED
Dec 14, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 30, 2020 EXRA
SOU EXTENSION 4 GRANTED
Jun 26, 2020 EX4G
SOU EXTENSION 4 FILED
Jun 26, 2020 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 26, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 12, 2019 EXRA
SOU EXTENSION 3 GRANTED
Dec 10, 2019 EX3G
SOU EXTENSION 3 FILED
Dec 10, 2019 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 10, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 25, 2019 EXRA
SOU EXTENSION 2 GRANTED
Jun 21, 2019 EX2G
SOU EXTENSION 2 FILED
Jun 21, 2019 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 21, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 20, 2018 EXRA
SOU EXTENSION 1 GRANTED
Nov 16, 2018 EX1G
SOU EXTENSION 1 FILED
Nov 16, 2018 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 16, 2018 EEXT
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jul 11, 2018 ASGN
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 26, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 1, 2018 NPUB
PUBLISHED FOR OPPOSITION
May 1, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 11, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 27, 2018 CNSA
ASSIGNED TO EXAMINER
Mar 27, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 13, 2018 NWOS
NEW APPLICATION ENTERED
Feb 8, 2018 NWAP

Related Trademarks

More from this Owner

XPERIENCE+

XPERIENCE+

XPERIENCE+

XPERIENCE+

XPERIENCE+

XPERIENCE+

SMARTSEE

SMARTSEE

ULTHERAPY PRIME

ULTHERAPY PRIME

ULTHERAPY PRIME

ULTHERAPY PRIME